Skip to main content

Table 2 Amendments to date

From: Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial

List of amendments

Summary of change

SA01

14/09/2016

• Personnel randomising to the trial has changed from pharmacy to research members as the randomisation software allows randomisation while protecting the blind

• Minor change to inclusion criteria – removed ‘modified RECIST’ from measurable disease section

SA02

25/01/2017

• Change to eligibility criteria – removed ‘measurable disease on CT (tumour thickness > 5 mm)’

• Dr. Steve Walker added as sub-investigator

• Radiological data collection is further explained in section 5.13

• Plan of analysis (Section 6.1) details how the radiological information will be used to calculate the sample size for the full study

SA03

26/04/2017

• Addition of Patient appointment schedule v1.0 22/03/17

SA04

08/09/2017

• Request to interview patients who decline participation in the trial

• Clarify number of patients for semi-structured interview (up to data saturation rather than the previously stated 10)

NSA01

20/09/2017

• Extend recruitment period by 1 month, to November 2017